Mark Smyth

Summary

Affiliation: Peter MacCallum Cancer Centre
Country: Australia

Publications

  1. pmc Multiple functions of CXCL12 in a syngeneic model of breast cancer
    SHARON A WILLIAMS
    School of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia, Australia
    Mol Cancer 9:250. 2010
  2. pmc Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice
    Jennifer A Westwood
    Cancer Immunology Research Program, Peter MacCallum Cancer Centre, Melbourne, Australia
    J Transl Med 8:42. 2010
  3. ncbi IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy
    Mark J Smyth
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Center, A Beckett Street, Victoria 8006, Australia
    J Immunol 176:6347-55. 2006
  4. ncbi CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer
    Mark J Smyth
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Australia
    J Immunol 176:1582-7. 2006
  5. pmc NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer
    Mark J Smyth
    Cancer Immunology Program, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, 8006, Victoria, Australia
    J Exp Med 200:1325-35. 2004
  6. ncbi Activation of NK cell cytotoxicity
    Mark J Smyth
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, VIC 8006, Australia
    Mol Immunol 42:501-10. 2005
  7. pmc Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer
    Mark J Smyth
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
    J Exp Med 201:1973-85. 2005
  8. pmc NKG2D function protects the host from tumor initiation
    Mark J Smyth
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    J Exp Med 202:583-8. 2005
  9. doi Interleukin 21 enhances antibody-mediated tumor rejection
    Mark J Smyth
    Cancer Immunology Program, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia
    Cancer Res 68:3019-25. 2008
  10. ncbi IL-21 induces the functional maturation of murine NK cells
    Jason Brady
    The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
    J Immunol 172:2048-58. 2004

Research Grants

Detail Information

Publications85

  1. pmc Multiple functions of CXCL12 in a syngeneic model of breast cancer
    SHARON A WILLIAMS
    School of Molecular and Biomedical Science, University of Adelaide, Adelaide, South Australia, Australia
    Mol Cancer 9:250. 2010
    ..To further elucidate its role in breast cancer progression, CXCL12 and its antagonist CXCL12(P2G) were overexpressed in the syngeneic 4T1.2 mouse model of breast carcinoma...
  2. pmc Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice
    Jennifer A Westwood
    Cancer Immunology Research Program, Peter MacCallum Cancer Centre, Melbourne, Australia
    J Transl Med 8:42. 2010
    ....
  3. ncbi IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy
    Mark J Smyth
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Center, A Beckett Street, Victoria 8006, Australia
    J Immunol 176:6347-55. 2006
    ..These results indicate that a rational combination of Ab-based therapy that causes tumor cell apoptosis and a cytokine that promotes T cell memory is a useful new strategy for cancer immunotherapy...
  4. ncbi CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer
    Mark J Smyth
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Australia
    J Immunol 176:1582-7. 2006
    ..Our data illustrate at least one mechanism by which Treg can suppress NK cell antitumor activity and highlight the effectiveness of combining Treg inhibition with subsequent NK cell activation to promote strong innate antitumor immunity...
  5. pmc NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer
    Mark J Smyth
    Cancer Immunology Program, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, 8006, Victoria, Australia
    J Exp Med 200:1325-35. 2004
    ....
  6. ncbi Activation of NK cell cytotoxicity
    Mark J Smyth
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, VIC 8006, Australia
    Mol Immunol 42:501-10. 2005
    ..This review will discuss the functional importance of NK cell cytotoxicity and the receptor/ligand interactions that control these processes...
  7. pmc Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer
    Mark J Smyth
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
    J Exp Med 201:1973-85. 2005
    ..Overall, the data suggest that NK cell antitumor function can be enhanced greatly by strategies that are designed to expand and differentiate NK cells via DC activation of NKT cells...
  8. pmc NKG2D function protects the host from tumor initiation
    Mark J Smyth
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    J Exp Med 202:583-8. 2005
    ..These findings suggest an important early role for the NKG2D in controlling and shaping tumor formation...
  9. doi Interleukin 21 enhances antibody-mediated tumor rejection
    Mark J Smyth
    Cancer Immunology Program, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia
    Cancer Res 68:3019-25. 2008
    ..These data further support the use of IL-21 in adjuvant settings where strong T cell-mediated immune responses to tumors can be generated...
  10. ncbi IL-21 induces the functional maturation of murine NK cells
    Jason Brady
    The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
    J Immunol 172:2048-58. 2004
    ..These developmental changes suggested that IL-21 functions to induce the terminal differentiation of mouse NK cells, resulting in heightened NK cell-mediated cytotoxicity and immune surveillance...
  11. ncbi Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice
    Erika Cretney
    Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, A Beckett Street, East Melbourne, 8006 Victoria, Australia
    J Immunol 168:1356-61. 2002
    ..TRAIL gene-targeted mice were also more sensitive to the chemical carcinogen methylcholanthrene. These results substantiated TRAIL as an important natural effector molecule used in the host defense against transformed cells...
  12. pmc Suppression of lymphoma and epithelial malignancies effected by interferon gamma
    Shayna E A Street
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Institute, East Melbourne, Victoria 8006, Australia
    J Exp Med 196:129-34. 2002
    ..A significant incidence of late onset adenocarcinoma observed in both IFN-gamma- and pfp-deficient mice indicated that some epithelial tissues were also subject to immunosurveillance...
  13. ncbi Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors
    Nicole M Haynes
    Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, Royal Melbourne Hospital Research Foundation, A Beckett Street, Victoria, Australia 8006
    Blood 100:3155-63. 2002
    ..Our study has illustrated the practical advantage of engineering a T-cell signaling complex that codelivers CD28 activation, dependent only upon the tumor's expression of the appropriate tumor associated antigen...
  14. ncbi NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy
    Yoshihiro Hayakawa
    Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    J Immunol 172:123-9. 2004
    ..These data suggested that NK cell TRAIL might regulate responses to vaccination by controlling the survival of Ag-loaded DC...
  15. ncbi Cutting edge: granzymes A and B are not essential for perforin-mediated tumor rejection
    Mark J Smyth
    Cancer Immunology Program, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
    J Immunol 171:515-8. 2003
    ....
  16. ncbi Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation
    Nicole M Haynes
    Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, St Andrew s Place, East Melbourne, Victoria, Australia
    J Immunol 169:5780-6. 2002
    ....
  17. ncbi T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner
    Michele W L Teng
    Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria 8006, Australia
    J Biol Chem 280:38235-41. 2005
    ..Overall, this study demonstrated the significant potential of suppressing tumors and other cellular targets expressing NKG2D-L by endowing T cells with innate NK cell-like function...
  18. pmc Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis
    Jeremy B Swann
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Proc Natl Acad Sci U S A 105:652-6. 2008
    ..Overall, these data not only confirm the key role that MyD88 plays in promoting tumor development but also demonstrate that inflammation-induced carcinogenesis and cancer immunoediting can indeed occur in the same mouse tumor model...
  19. ncbi Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin
    Yoshihiro Hayakawa
    Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, A Beckett Street, St Andrews Place, East Melbourne, 8006 Victoria, Australia
    J Immunol 169:5377-81. 2002
    ..Thus, these results indicated that NKG2D acted as a natural cytotoxicity receptor to stimulate perforin-mediated elimination of ligand-expressing tumor cells...
  20. pmc Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis
    Yoshihiro Hayakawa
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett Street, Melbourne 8006, Australia
    Proc Natl Acad Sci U S A 100:9464-9. 2003
    ..Taken together, our results demonstrate that NK1.1+alphabetaTCR+ cell-based immune therapy can inhibit primary tumorigenesis...
  21. ncbi Combined natural killer T-cell based immunotherapy eradicates established tumors in mice
    Michele W L Teng
    Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Cancer Res 67:7495-504. 2007
    ..In summary, sequential tumor cell apoptosis and amplification of dendritic cell function by NKT cell agonists represents an exciting and novel approach for cancer treatment...
  22. doi Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion
    Michele W L Teng
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Cancer Res 70:2665-74. 2010
    ..These studies reveal that Tregs control multiple redundant elements of the immune effector response capable of inhibiting tumor initiation and underscore the importance of effectively targeting these cells in any cancer immunotherapy...
  23. ncbi Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide
    Mark J Smyth
    Cancer Immunology, Trescowthick Laboratories, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
    Blood 99:1259-66. 2002
    ....
  24. ncbi NKT cells - conductors of tumor immunity?
    Mark J Smyth
    Cancer Immunology, Trescowthick Laboratories, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
    Curr Opin Immunol 14:165-71. 2002
    ....
  25. pmc Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells
    Shayna E A Street
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre Peter Mac, 8006, Victoria, Australia
    J Exp Med 199:879-84. 2004
    ..These results reflect a critical role for NK cells and gammadeltaTCR+ T cells in innate immune surveillance of B cell lymphomas, mediated by as yet undetermined pathway(s) of tumor recognition...
  26. ncbi Distinct receptor repertoire formation in mouse NK cell subsets regulated by MHC class I expression
    Yoshihiro Hayakawa
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, Australia, 3002
    J Leukoc Biol 83:106-11. 2008
    ....
  27. pmc Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice
    Jennifer A Westwood
    Cancer Immunology Program and Department of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, St Andrew s Place, Melbourne, Victoria 3002, Australia
    Proc Natl Acad Sci U S A 102:19051-6. 2005
    ..This study supports the use of humanized gene-modified T cells as a potential therapy for Le(Y+) malignancies...
  28. doi DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases
    Christopher J Chan
    Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    J Immunol 184:902-11. 2010
    ....
  29. ncbi Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer
    Michael H Kershaw
    Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    J Immunol 173:2143-50. 2004
    ..T cell adjuvant treatment of day 8 metastatic disease resulted in dramatic increases in survival of mice, and this survival was significantly greater than that afforded by either doxorubicin, 5-fluorouracil, or herceptin...
  30. doi Characterizing the anti-tumor function of adoptively transferred NK cells in vivo
    Hollie J Pegram
    Cancer Immunology Program, Cancer Immunotherapy Research Laboratory, Peter MacCallum Cancer Centre, 14 St Andrews Place, East Melbourne, Vic, 3002, Australia
    Cancer Immunol Immunother 59:1235-46. 2010
    ..Overall, the results of this study have important implications for enhancing NK cell-based immunotherapies...
  31. ncbi Adoptive transfer of chimeric FcepsilonRI gene-modified human T cells for cancer immunotherapy
    Michele W L Teng
    Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 8006, Australia
    Hum Gene Ther 17:1134-43. 2006
    ....
  32. ncbi NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation
    Nicholas D Huntington
    Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
    J Immunol 178:4764-70. 2007
    ..These data indicate that NK cells acquire KLRG1 on their surface during development, and this expression correlates with functional distinctions from other peripheral NK cells in vivo...
  33. ncbi Functional analysis of granzyme M and its role in immunity to infection
    Lily I Pao
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    J Immunol 175:3235-43. 2005
    ..These data confirm a role for GrzM in the host response to MCMV infection, but suggest that GrzM is not critical for NK cell-mediated cytotoxicity...
  34. ncbi Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells
    Nadine Y Crowe
    Department of Pathology and Immunology, Monash University, Central and Eastern Clinical School, Prahran, Victoria, Australia
    J Immunol 171:4020-7. 2003
    ..This study provides critical new insight into how NKT cells can have such a major impact on immune responses, lasting many days beyond the initial stimulation of these cells...
  35. ncbi A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo
    Janice M Kelly
    Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia
    J Immunol 168:4472-9. 2002
    ..Our findings demonstrate a key role for IFN-gamma in innate and adaptive immunity triggered by CD80 expression on tumor cells...
  36. ncbi Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection
    Janice M Kelly
    Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, Victoria, Australia
    Nat Immunol 3:83-90. 2002
    ..Thus CD27-CD70 interactions provide a key link between innate NK cell responses and adaptive T cell immunity...
  37. pmc Differential antitumor immunity mediated by NKT cell subsets in vivo
    Nadine Y Crowe
    Department of Microbiology and Immunology, University of Melbourne, Victoria, Australia
    J Exp Med 202:1279-88. 2005
    ....
  38. pmc NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge
    Adam P Uldrich
    Department Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia
    J Immunol 175:3092-101. 2005
    ..In summary, this study significantly enhances our understanding of how NKT cells respond to primary and secondary antigenic challenge in vivo...
  39. doi Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion
    Joe Wei
    Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Melbourne, Victoria, Australia
    J Immunol 185:6013-22. 2010
    ..These observations suggest that IAV infection of tumor cells may facilitate improved cross-presentation of tumor Ags and may be used to augment clinical vaccine efficacy...
  40. pmc CD1d-based combination therapy eradicates established tumors in mice
    Michele W L Teng
    Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    J Immunol 183:1911-20. 2009
    ....
  41. doi Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity
    Henrik S√łndergaard
    Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    J Immunol 183:7326-36. 2009
    ....
  42. ncbi Innate tumor immune surveillance
    Mark J Smyth
    Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, 3002, Victoria, Australia
    Adv Exp Med Biol 590:103-11. 2007
  43. ncbi Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes
    Michele W L Teng
    Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, Melbourne 8006, Australia
    Hum Gene Ther 15:699-708. 2004
    ..These preclinical studies are an important proof of principle that human T cells may be genetically redirected to tumors in cancer patients...
  44. pmc IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis
    Michele W L Teng
    Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
    Proc Natl Acad Sci U S A 107:8328-33. 2010
    ..Overall, these data indicate the general role that IL-23 plays in suppressing natural or cytokine-induced innate immunity, promoting tumor development and metastases independently of IL-17A...
  45. ncbi New aspects of natural-killer-cell surveillance and therapy of cancer
    Mark J Smyth
    Cancer Immunology Laboratory, Trescowthick Research Laboratories, Research Division, Peter MacCallum Cancer Institute, Locked Bag 1, A Beckett Street, Melbourne 8006, Australia
    Nat Rev Cancer 2:850-61. 2002
  46. ncbi Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells
    Maria Moeller
    Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Cancer Res 67:11428-37. 2007
    ..These data support the use of gene-modified CD4(+) Th1 and CD8(+) T cells for mediating a sustained antitumor response...
  47. ncbi Type I IFN contributes to NK cell homeostasis, activation, and antitumor function
    Jeremy B Swann
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, 8006 Victoria, Australia
    J Immunol 178:7540-9. 2007
    ..This study demonstrates that endogenous type I IFN is a central mediator of NK cell antitumor responses...
  48. ncbi Granzyme M mediates a novel form of perforin-dependent cell death
    Janice M Kelly
    Cancer Immunology Program, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, 8006 Victoria, Australia
    J Biol Chem 279:22236-42. 2004
    ..These data raise the likelihood that granzyme M represents a third major and specialized perforin-dependent cell death pathway that plays a significant role in death mediated by NK cells...
  49. pmc Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist
    Ailsa J Frew
    Cancer Immunology Program, The Peter MacCallum Cancer Centre, Trescowthick Research Laboratories, St Andrews Place, East Melbourne 3002, Victoria, Australia
    Proc Natl Acad Sci U S A 105:11317-22. 2008
    ..These data demonstrate that combination therapies involving HDACi and activators of the TRAIL pathway can be efficacious for the treatment of cancer in experimental mouse models...
  50. ncbi Calcium-dependent plasma membrane binding and cell lysis by perforin are mediated through its C2 domain: A critical role for aspartate residues 429, 435, 483, and 485 but not 491
    Ilia Voskoboinik
    Cancer Immunology Program, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St 8006 and The Walter and Eliza Hall Institute for Medical Research, 1G Royal Parade, Parkville, Victoria 3050, Australia
    J Biol Chem 280:8426-34. 2005
    ..Finally, after experimentally verifying an optimized three-dimensional model, we have made predictions on the impact of two inherited perforin mutations of the C2 domain on calcium-dependent lipid binding and cell lysis...
  51. ncbi Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection
    Maria Moeller
    Cancer Immunology Program, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, East Melbourne, 8006, Victoria, Australia
    Blood 106:2995-3003. 2005
    ..Overall, this study has highlighted the therapeutic potential of using combined transfer of antigen-specific gene-modified CD8+ and CD4+ T cells to significantly enhance T-cell adoptive transfer strategies for cancer therapy...
  52. ncbi Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway
    Jennifer A Westwood
    Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Centre, A Beckett Street, East Melbourne, 8006 Victoria, Australia
    J Immunol 172:757-61. 2004
    ....
  53. ncbi IFN-gamma-dependent recruitment of mature CD27(high) NK cells to lymph nodes primed by dendritic cells
    Sally V Watt
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St Andrews Place, Victoria, Australia
    J Immunol 181:5323-30. 2008
    ..Thus, our results identify that CD27(high) NK cells are the dominant population recruited to the draining LN and NK cell recruitment requires endogenous IFN-gamma in coordinating with DC migration...
  54. ncbi DX5/CD49b-positive T cells are not synonymous with CD1d-dependent NKT cells
    Daniel G Pellicci
    University of Melbourne, Department of Microbiology and Immunology, Parkville, Victoria, Australia
    J Immunol 175:4416-25. 2005
    ..In summary, our data demonstrate that DX5/CD49b is a poor marker for identifying CD1d-dependent NKT cells...
  55. ncbi Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo
    Hollie J Pegram
    Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    J Immunol 181:3449-55. 2008
    ..p. RMA-erbB2(+) lymphoma. In summary, these data suggest that use of genetically modified NK cells could broaden the scope of cancer immunotherapy for patients...
  56. doi No requirement for TRAIL in intrathymic negative selection
    Erika Cretney
    Cancer Immunology Program, Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia
    Int Immunol 20:267-76. 2008
    ..These results, combined with the fact that aged C57BL/6 TRAIL(-/-) mice showed no signs of spontaneous autoimmunity, strongly indicate that intrathymic negative selection occurs normally in the absence of TRAIL signaling...
  57. pmc CD1d activation and blockade: a new antitumor strategy
    Michele W L Teng
    Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    J Immunol 182:3366-71. 2009
    ..The ability of anti-CD1d mAbs to coincidently activate CD1d(+) APCs to release IL-12 and inhibit CD1d-restricted type II NKT cells makes CD1d an exciting new target for immunotherapy of cancer based on tumor immunoregulation...
  58. ncbi Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis
    Jonathan M Coquet
    Department of Microbiology and Immunology, University of Melbourne, Parkville, Victoria, Australia
    J Immunol 180:7097-101. 2008
    ..Thus, our results challenge the notion that IL-21 is a key factor in driving Th17 immunity and disease...
  59. ncbi Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma
    Shayna E A Street
    Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    Cancer Res 67:5454-60. 2007
    ..This data suggests that perforin may mediate some suppression of epithelial carcinogenesis by intervening early in the tumor development process...
  60. pmc Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells
    Irina Caminschi
    Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, 3050, Australia
    J Exp Med 204:2579-90. 2007
    ..Thus, IKDCs resemble NK cells functionally, and neither cell type could be induced to be effective antigen-presenting cells...
  61. ncbi Nature's TRAIL--on a path to cancer immunotherapy
    Mark J Smyth
    Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, East Melbourne, Victoria 3002, Australia
    Immunity 18:1-6. 2003
    ....
  62. pmc Normal thymocyte negative selection in TRAIL-deficient mice
    Erika Cretney
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett St, Melbourne, Victoria 8006, Australia
    J Exp Med 198:491-6. 2003
    ..We were unable to demonstrate a role for TRAIL signaling in any of these models, suggesting that this pathway is not a critical factor for thymocyte negative selection...
  63. ncbi A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells
    Maria Moeller
    Cancer Immunology Program, Sir Donald and Lady Trescowthick Laboratories, Peter MacCallum Cancer Institute, St Andrews Place, East Melbourne, Victoria, Australia
    Cancer Gene Ther 11:371-9. 2004
    ....
  64. ncbi Innate immune recognition and suppression of tumors
    Yoshihiro Hayakawa
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia
    Adv Cancer Res 95:293-322. 2006
    ..Evidence clearly implicate that NKG2D recognition plays an important role in tumor immune surveillance...
  65. ncbi Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome
    Linda Mileshkin
    Division of Haematology and Medical Oncology, Department of Haematology and Medical Oncology, Peter MacCallum Cancer Center, St Andrew s Place, East Melbourne, Vic, Australia
    Haematologica 92:1075-82. 2007
    ..We assessed laboratory and clinical parameters in patients with myeloma treated with thalidomide as potential prognostic markers and looked for changes with therapy...
  66. ncbi Reversal in the immunodominance hierarchy in secondary CD8+ T cell responses to influenza A virus: roles for cross-presentation and lysis-independent immunodomination
    Weisan Chen
    T Cell Laboratory, Ludwig Institute for Cancer Research, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia
    J Immunol 173:5021-7. 2004
    ..We further show that immunodomination of PA(224-233)-specific TCD8+ by nucleoprotein 366-374-specific TCD8+ plays a critical role in the phenomena, and that this is unlikely to be mediated by TCD8+ lysis of APCs or other cells...
  67. pmc A natural killer T (NKT) cell developmental pathway iInvolving a thymus-dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage
    Daniel G Pellicci
    Department of Immunology and Pathology, Monash University Medical School, Prahran, Victoria 3181, Australia
    J Exp Med 195:835-44. 2002
    ..1(-). Further elucidation of this NKT cell developmental pathway should prove to be invaluable for studying the mechanisms that regulate the development of these cells...
  68. ncbi TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver
    Kazuyoshi Takeda
    Department of Immunology, Juntendo University School of Medicine, 2 1 1 Hongo, Bukyou ku, Tokyo 113 8421, Japan
    Blood 105:2082-9. 2005
    ..This study is the first to describe the concomitant maturation of NK cell effector function with surface phenotype in vivo and implies an important defense role for NK cell TRAIL in the developing immune system...
  69. ncbi Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin
    Naoko Seki
    Laboratory of Experimental Immunology, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA
    J Immunol 168:3484-92. 2002
    ..Therefore, although granule-mediated killing is of paramount importance for CTL-mediated lysis in vitro, some major in vivo effector mechanisms clearly are independent of perforin...
  70. ncbi Eradication of established tumors in mice by a combination antibody-based therapy
    Tomoyasu Uno
    Department of Immunology, Juntendo University School of Medicine, Hongo 2 1 1, Bunkyo ku, Tokyo 113 8421, Japan
    Nat Med 12:693-8. 2006
    ..These results in mice indicate that a rational monoclonal antibody-based therapy that both causes tumor-cell apoptosis through DR5 and activates T cells may be an effective strategy for cancer immunotherapy in humans...
  71. pmc IFN-gamma-mediated negative feedback regulation of NKT-cell function by CD94/NKG2
    Tsuyoshi Ota
    Department of Immunology, Juntendo University School of Medicine, 2 1 1 Hongo, Bunkyo ku, Tokyo 113 8421, Japan
    Blood 106:184-92. 2005
    ....
  72. pmc Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development
    Kazuyoshi Takeda
    Department of Immunology, Juntendo University, School of Medicine, Bunkyo ku, Tokyo 113 8421, Japan
    J Exp Med 195:161-9. 2002
    ..Moreover, development of spontaneous tumors in p53(+/-) mice was also promoted by neutralization of TRAIL. These results indicated a substantial role of TRAIL as an effector molecule that eliminates developing tumors...
  73. ncbi IL-21 enhances tumor rejection through a NKG2D-dependent mechanism
    Rayna Takaki
    Department of Microbiology and Immunology, Biomedical Sciences Graduate Program and The Cancer Research Institute, University of California, San Francisco, CA 94143, USA
    J Immunol 175:2167-73. 2005
    ..Collectively, these findings suggest that IL-21 therapy may work optimally against tumors that can elicit a NKG2D-mediated immune response...
  74. ncbi Calreticulin exposure increases cancer immunogenicity
    Chris Clarke
    Nat Biotechnol 25:192-3. 2007
  75. ncbi Blastocyst MHC, a putative murine homologue of HLA-G, protects TAP-deficient tumor cells from natural killer cell-mediated rejection in vivo
    Atsushi Tajima
    Department of Immunology and Obstetrics and Gynecology, Juntendo University School of Medicine, Tokyo, Japan
    J Immunol 171:1715-21. 2003
    ..These results suggested a role for blastocyst MHC in protecting TAP-deficient trophoblasts and tumor cells from NK cell attack in vivo...
  76. pmc NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs
    Edward S Morris
    Queensland Institute of Medical Research, Brisbane, Queensland, Australia
    J Clin Invest 115:3093-103. 2005
    ....
  77. pmc Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas
    Claudia Curcio
    Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Italy
    J Clin Invest 111:1161-70. 2003
    ..Moreover, vaccination cured half of the CD1 and the majority of the MCP1 KO mice. The eradication of established p185(neu) carcinomas involves distinct mechanisms, each endowed with a different curative potential...
  78. ncbi Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer
    Naoko Seki
    Laboratory of Experimental Immunology, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland 21702 1201, USA
    Cancer Res 63:207-13. 2003
    ..Consequently, the efficacy of TRAIL therapy may vary depending on the location of the tumor metastases...
  79. ncbi NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function
    Karen Abdool
    Laboratory of Experimental Immunology, National Cancer Institute Frederick, Building 560, Frederick, MD 21702, USA
    J Immunol 177:2575-83. 2006
    ....
  80. ncbi Functional interactions between dendritic cells and NK cells during viral infection
    Daniel M Andrews
    Department of Microbiology, School of Biomedical and Chemical Sciences, The University of Western Australia, Nedlands, Perth, Australia
    Nat Immunol 4:175-81. 2003
    ..This study provides evidence for a functional interrelationship between DCs and NK cells during viral infection and defines some of the critical cytokines...
  81. ncbi NK cells contribute to the early clearance of HSV-1 from the lung but cannot control replication in the central nervous system following intranasal infection
    Patrick C Reading
    Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Australia
    Eur J Immunol 36:897-905. 2006
    ....
  82. ncbi Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells
    Trina J Stewart
    Centre for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland, 4102, Australia
    Cancer Res 63:3058-60. 2003
    ..This suggests that recruitment/activation of J alpha 18(+) NKT cells is an important consideration during the immune therapy of early stage tumors...
  83. pmc Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis
    Amanda C Stanley
    Immunology and Infection Laboratory, Queensland Institute of Medical Research, Herston, Queensland, Australia
    PLoS Pathog 4:e1000028. 2008
    ..Our data clearly illustrate the double-edged sword of NKT cell-based therapy, showing that in some circumstances, such as when sub-clinical or chronic infections exist, iNKT cell activation can have adverse outcomes...
  84. ncbi IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide
    Yoshihiro Hayakawa
    Department of Pathogenic Biochemistry, Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, Japan
    Blood 100:1728-33. 2002
    ..These results suggest that the IFN-gamma-mediated inhibition of tumor angiogenesis is critically involved in the effector mechanisms of antitumor effects evoked by alpha-GalCer...
  85. pmc A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas
    Nadine Y Crowe
    Department of Pathology and Immunology, Monash University Medical School, Melbourne, Victoria 3181, Australia
    J Exp Med 196:119-27. 2002
    ....

Research Grants4

  1. The regulation of tumor immunity by NKT cells
    Mark Smyth; Fiscal Year: 2007
    ..This proposal focuses clearly on a pivotal immune control mechanism that will influence many current and future immunotherapies. ..